drugset / Trial / NCT07509684
A Phase Ib/II Study Evaluating Injectable ALK-N001 in Patients With Advanced Solid Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study is a multicenter, open-label, dose-escalation and cohort-expansion Phase Ib/II clinical trial conducted in patients with advanced solid tumors, aiming to evaluate the safety, pharmacokinetics and efficacy of ALK-N001 for injection as monotherapy in the treatment of advanced solid tumors.
Timeline
- Start
- 2026-04
- Primary completion
- 2027-12
- Completion
- 2029-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ALK-N001 | Unknown | 37.5 mg/m2 | Intravenous |
| Subject | ALK-N001 | Unknown | 50 mg/m2 | Intravenous |
| Subject | ALK-N001 | Unknown | 62.5 mg/m2 | Intravenous |